How Regenerative Medicine Committee Review Works in Japan

Japan's regenerative medicine framework does not leave the question of "who checks this before treatment begins" unanswered. Before certain medical institutions can offer regenerative medicine, a review body — a certified committee — examines the provider's plan. That review covers regulatory compliance, and scientific and ethical considerations built into the plan itself.

It's worth being direct from the outset about what this review is and isn't. Committee review is a regulatory process — a structured examination of documentation, procedures, and safeguards. It is not a scientific verdict on whether a specific treatment works, and it does not replace the kind of evidence review a physician or researcher would separately conduct. Understanding the difference between "this plan was reviewed" and "this treatment is proven" is the central thread running through everything below.

What Is a Certified Committee Under Japan's Regenerative Medicine Law?

Japan's Act on the Safety of Regenerative Medicine requires every regenerative medicine provision plan to be reviewed by a certified committee before treatment can begin. These committees aren't government offices — they are bodies of outside experts, accredited by the Ministry of Health, Labour and Welfare, whose job is to examine a plan against the law's provision standards before an institution can offer the treatment it describes.

There are two tiers. A Certified Special Committee for Regenerative Medicine (CSCRM) reviews Category I and Category II plans — the higher-oversight tiers — and is required to have at least eight members, including expertise in a relevant scientific field. A Certified Committee for Regenerative Medicine (CCRM) reviews Category III plans, the lighter-oversight tier, and has comparatively less stringent membership and expertise requirements than a CSCRM.

A committee's relationship to the provider is worth stating plainly: the committee reviews the institution's plan, not the institution itself in some ongoing sense, and it reviews that plan before treatment is offered, not after. The Act positions the committee as the gatekeeper between "an institution wants to offer this treatment" and "an institution may offer this treatment" — everything before that point is preparation; everything after is the ongoing obligations described later in this article.

Which committee reviews a plan reflects the technology's assessed risk category — it does not indicate how effective the treatment is, and neither tier's review certifies clinical outcomes.

How Does the Committee Review Process Work?

The process follows a defined sequence:

1. The provider prepares a regenerative medicine provision plan. This document describes the institution and its administrator, the regenerative medicine to be provided, the personnel, structure, and equipment involved, the method of obtaining and processing cells, and the safety and bioethical measures in place.
2. The relevant certified committee reviews the documentation. Which tier of committee — CSCRM or CCRM — depends on the risk category the plan falls under.
3. The committee assesses the plan against the required aspects described below, examining it in light of the law's provision standards rather than issuing a judgment on clinical outcomes.
4. The provider submits required notifications, including the plan itself and the committee's opinion, to the Ministry — for Category I plans specifically, treatment cannot begin until a fixed waiting period has elapsed after submission. Once accepted, the plan receives a regulatory plan number confirming it has been reviewed.
5. Ongoing obligations continue after provision begins — this isn't a one-time checkpoint; reporting requirements persist for as long as the institution offers the treatment, covered in more detail further down.

Throughout this process, the committee reviews, examines, and assesses compliance with the plan's documentation and procedural requirements — not, as the next section explains, the treatment's effectiveness.

What Does the Committee Actually Review?

A committee's examination is meant to cover the plan comprehensively, not just its paperwork. In practice, this includes:

• Scientific rationale — what the plan states about why the proposed intervention is appropriate for its stated purpose.
• Risk management — how the institution plans to identify and respond to complications.
• Cell processing considerations — the method of obtaining cells and the quality-control process applied before they're used.
• Safety procedures — screening, clean-room or equivalent processing conditions, and post-treatment monitoring.
• Informed consent — how the institution intends to inform patients before they agree to treatment.
• Monitoring plans — what the institution commits to tracking once treatment begins.

It's worth restating the boundary here clearly: this is a review of process — does the plan describe adequate safeguards across these categories — not a review of outcome. A plan can pass this examination while the underlying scientific evidence for a specific intervention's effectiveness is still developing elsewhere in the literature. Those are two separate questions, and committee review only answers the first one.

How Are Different Risk Categories Reviewed?

Japan's regenerative medicine framework sorts technologies into three risk-based categories — a system covered in full in our Category I, II, and III explainer. What matters here is simpler: the risk category a plan falls under determines which review pathway applies, not what the treatment is worth or how well it's expected to work.

Category I and Category II plans go to a CSCRM — the higher-oversight committee tier described above — reflecting the law's judgment that these technologies carry greater uncertainty or risk and warrant a more stringently composed reviewing body. Category III plans go to a CCRM, a lighter-oversight tier appropriate to technologies the law treats as carrying comparatively lower risk. Neither pathway is "stricter" in a way that reflects treatment quality — the pathway simply matches the review body's composition requirements to the technology's assessed risk profile, the same distinction our Category I/II/III explainer covers in detail.

Why Committee Independence and Conflict Management Matter

This is worth addressing directly rather than glossing over, because it's genuinely part of understanding how the system works. Japan's Act on the Safety of Regenerative Medicine does not simply assume every certified committee is automatically independent from the institution whose plan it reviews — the law itself permits a hospital or clinic's own founder to establish a committee, without a blanket organizational-separation requirement.

Independent, peer-reviewed research has examined how this plays out in practice. A 2023 analysis published in Stem Cell Reports documented specific patterns raising integrity questions — including committees sharing a physical address with a cell-processing company, a committee employee simultaneously employed by a cell processor, committee meetings held inside a cell-processing company's own offices, and a committee advertising document-preparation services to institutions it reviews. The same analysis found that 65% of the therapeutic plans it examined used duplicated materials across different institutions, suggesting template reuse rather than independent, case-by-case review in at least some instances. The authors concluded that "the prevalence and closeness of such relationships between providers, CSCRMs, and intermediary parties raise serious questions about the integrity and independence of the review process."

This isn't a reason to dismiss the framework, and it shouldn't be read as an attack on Japanese regulation generally. The more accurate reading is the opposite: MHLW's own guidance for certified committees includes a dedicated conflict-of-interest management section, and a 2025 amendment to the law's subordinate regulations introduced stricter conflict-of-interest management requirements alongside new scientific-validity and outcome-reporting obligations. The existence of these requirements reflects the fact that regulatory systems continuously evolve — a live, regulator-acknowledged area of active revision, not a static or ignored problem. Knowing this history is part of reading committee review accurately: it's a real process with real oversight, and also a process where independent scrutiny has found real limitations worth being aware of.

What Happens After Committee Review?

Committee review isn't a single checkpoint that closes the file once a plan is accepted. The law builds in ongoing obligations for as long as an institution offers the reviewed treatment:

• Adverse event reporting. Diseases, disabilities, deaths, or suspected infections connected to the treatment must be reported — to the reviewing committee, and to the Minister.
• Periodic reporting. Institutions must periodically report on the status of the regenerative medicine they're providing, both to their certified committee and to the Minister.
• Public disclosure. Results of this periodic reporting are made public, rather than held privately between the institution and the regulator.

These obligations mean committee review functions less like a one-time gate and more like the start of an ongoing reporting relationship — though, as with the review itself, this reporting structure is a compliance and transparency mechanism, not a real-time guarantee that every issue will be caught immediately as it happens.

Does Committee Review Mean a Treatment Is Proven Safe or Effective?

No. This is worth answering as directly as possible, because it's the question underneath most of what makes this system easy to misread.

Committee review confirms that a provision plan addresses the regulatory requirements described throughout this article — documentation, safety procedures, cell-processing methods, monitoring plans, and reporting commitments. It does not replace a separate evaluation of clinical evidence, and it is not a certification that a specific treatment is effective for a specific condition. A plan can be reviewed and accepted while the scientific evidence behind a given intervention continues to develop, and those two facts are not in tension with each other — they're simply different questions, addressed through different processes.

If you're trying to understand what a specific treatment can realistically do, committee review is not the resource to look to for that answer. It's a resource for understanding whether an institution's plan meets Japan's procedural and safety requirements — a real and meaningful thing to know, just not the same thing as an effectiveness verdict. For a broader look at how Japan regulates regenerative medicine safety, see our safety overview of stem cell therapy in Japan.

How International Patients Can Understand the Process

Rather than treating "was this reviewed by a committee" as a single yes/no checkbox, it's more useful to ask a few specific questions:

• What category applies to this treatment, and does that match what you'd expect given the technology involved?
• What committee reviewed this specific plan — a CSCRM or a CCRM — and is that the tier the category actually requires?
• What evidence supports the intervention itself, separate from the fact that its provision plan was reviewed?
• What is the provider's own experience with this specific treatment, and how do they describe their monitoring and follow-up process?

These are reasonable, answerable questions for any institution to field — not an unusual level of scrutiny. This article isn't a guide to evaluating or recommending any specific clinic; it's a starting point for understanding what committee review actually establishes, so the questions you bring to a provider are grounded in how the system actually works.

StemCellor's Role in This Process

StemCellor is a Japan-based medical coordination service for international patients navigating regenerative medicine options in Japan. Its role here is to help organize information and support communication between you and the licensed physicians or institutions who make the actual clinical and regulatory decisions. StemCellor does not operate as a treatment provider, does not submit or hold a regenerative medicine provision plan, and does not evaluate or approve any institution's committee or treatment on a patient's behalf.

Frequently asked questions

What is a regenerative medicine certified committee in Japan?

It's a body of outside experts — accredited by the Ministry of Health, Labour and Welfare — that reviews a regenerative medicine provision plan against Japan's legal requirements before an institution can offer that treatment. There are two tiers: CSCRM (for Category I and II plans) and CCRM (for Category III plans).

Does committee review mean regenerative medicine treatment is approved?

Not in the sense of a government endorsement of effectiveness. Committee review confirms that a specific institution's plan meets the procedural, documentation, and safety requirements that apply to its risk category — it does not certify that the treatment works or guarantee any clinical outcome.

What is the difference between CSCRM and CCRM?

A CSCRM (Certified Special Committee for Regenerative Medicine) reviews the higher-oversight Category I and II plans and requires at least eight members with relevant scientific expertise. A CCRM (Certified Committee for Regenerative Medicine) reviews Category III plans and has comparatively lighter membership and expertise requirements.

Who reviews regenerative medicine plans in Japan?

A certified committee — CSCRM or CCRM depending on the plan's risk category — reviews each provision plan. The law does not require this committee to be organizationally independent from the institution whose plan it reviews, which is why independent conflict-of-interest research and MHLW's own conflict-management requirements are both relevant context.

Does committee review guarantee treatment safety?

No. It confirms that a plan addresses the required safety procedures, documentation, and monitoring commitments — it is a process and compliance review, not a guarantee that a specific patient will have a specific outcome.

What should international patients ask about committee review?

It's reasonable to ask which category applies to a treatment, which tier of committee reviewed the specific plan, what independent evidence supports the intervention itself, and what the provider's own experience and monitoring process look like — rather than treating "it was reviewed" alone as a complete answer.

References

"Act on the Safety of Regenerative Medicine" (Act No. 85 of 2013, as amended), official English translation, Japanese Law Translation Database System, Ministry of Justice, Japan.

Tsunakuni I, Fujita M, Hatta T, Isobe T, Konomi K, Onishi T, Sanada S, Sato Y, Tashiro S, Tobita M. "Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan." Stem Cell Reports. 2023;18(3):613-617. DOI: 10.1016/j.stemcr.2023.01.013

Hosoya S, Ukon Y, Morita K, Minegishi E, Sugihara J, Hasegawa M. "Detailed revisions to the subordinate regulation following the amendment of the Act on the Safety of Regenerative Medicine in Japan." Regenerative Therapy. 2025;30:217-223. DOI: 10.1016/j.reth.2025.06.006

認定再生医療等委員会 (Certified Committees for Regenerative Medicine) — official guidance page, Ministry of Health, Labour and Welfare (厚生労働省).